Skip to main content

Clinical Trials Using Venetoclax

Review the clinical trials studying venetoclax on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 156

Cladribine Plus Venetoclax for the Treatment of AML That is Relapsed or Refractory to Venetoclax and a Hypomethylating Agent
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Venetoclax and Rituximab for the Initial Treatment of Older Patients with Untreated Mantle Cell Lymphoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Acalabrutinib in Combination with Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination of Pirtobrutinib and Venetoclax for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax with Standard Remission Induction Chemotherapy for the Treatment of Patients with Secondary Acute Myeloid Leukemia
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Untreated Chronic Lymphocytic Leukemia or Untreated, Recurrent, or Refractory Richter Transformation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ivosidenib or Enasidenib plus Azacitidine followed by Venetoclax plus Azacitidine compared to Venetoclax plus Azacitidine followed by Ivosidenib or Enasidenib plus Azacitidine for the Treatment of IDH Mutated Acute Myeloid Leukemia, I-DATA Trial
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Calaspargase Pegol-mknl and Decitabine Combined with Venetoclax for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 2 locations
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Comparing Cyclophosphamide, Sirolimus, Ruxolitinib to Cyclophosphamide, Sirolimus, Mycophenolate Mofetil after Allogeneic Stem Cell Transplantation for the Prevention of Graft versus Host Disease in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Venetoclax, Tagraxofusp, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Induction and Consolidation with Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Venetoclax for Maintenance Treatment in Patients with AML and MDS After Donor Stem Cell Transplant
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Decitabine/Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Duvelisib and Venetoclax for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California